Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Other Accumulated Expenses (2016 - 2017)

Agios Pharmaceuticals (AGIO) has disclosed Other Accumulated Expenses for 5 consecutive years, with $1.3 million as the latest value for Q1 2017.

  • For the quarter ending Q1 2017, Other Accumulated Expenses rose 386.84% year-over-year to $1.3 million, compared with a TTM value of $1.3 million through Mar 2017, up 386.84%, and an annual FY2016 reading of $168000.0, down 87.21% over the prior year.
  • Other Accumulated Expenses was $1.3 million for Q1 2017 at Agios Pharmaceuticals, up from $168000.0 in the prior quarter.
  • Across five years, Other Accumulated Expenses topped out at $1.3 million in Q4 2015 and bottomed at $4000.0 in Q1 2015.
  • Average Other Accumulated Expenses over 4 years is $521909.1, with a median of $415000.0 recorded in 2013.
  • Peak annual rise in Other Accumulated Expenses hit 6550.0% in 2016, while the deepest fall reached 87.21% in 2016.
  • Year by year, Other Accumulated Expenses stood at $426000.0 in 2013, then soared by 208.45% to $1.3 million in 2015, then plummeted by 87.21% to $168000.0 in 2016, then soared by 670.83% to $1.3 million in 2017.
  • Business Quant data shows Other Accumulated Expenses for AGIO at $1.3 million in Q1 2017, $168000.0 in Q4 2016, and $538000.0 in Q3 2016.